Title

Inhibition of Mul1-mediated ubiquitination promotes mitochondria-associated translation

Authors

Yuan Gao[1], Maria Dafne Cardamone[1], Julian Kwan[1,2], Joseph Orofino[1], Ryan Hekman[1,2], Shawn

Lyons[1], Andrew Emili[1,2,3], Valentina Perissi[1,4]

[1] Biochemistry Department, Boston University School of Medicine, Boston, MA 02115

[2] Center for Network and Systems Biology, Boston University, Boston, MA 02115

[3] Biology Department, Boston University, Boston, MA 02115

[4] Corresponding Author

Keywords

Ubiquitin, GPS2, mitochondria, PABPC, Mul1, mitochondria stress response (MSR)

Running title

Regulation of mitochondria-associated translation by GPS2

ABSTRACT

G-Protein Pathway Suppressor 2 (GPS2) was recently identified as an endogenous inhibitor of non-proteolytic ubiquitination mediated by the E2 ubiquitin-conjugating enzyme Ubc13. GPS2-mediated restriction of K63 ubiquitination is associated with the regulation of insulin signaling, inflammation and mitochondria-nuclear communication, however a detailed understanding of the targets of GPS2/Ubc13 activity is currently lacking, Here, we have dissected the GPS2-regulated K63 ubiquitome in mouse embryonic fibroblasts and human breast cancer cells, unexpectedly finding an enrichment for proteins involved in RNA binding and translation. Characterization of putative targets, including the RNA-binding protein PABPC1 and translation factor eiF3m, revealed a strategy for regulating the mitochondria-associated translation of selected mRNAs via Mul1-mediated ubiquitination. Our data indicate that removal of GPS2-mediated inhibition, either via genetic deletion or stress-induced nuclear translocation, promotes the ubiquitination of mitochondria-associated translation factors leading to increased expression of an adaptive antioxidant program. In light of GPS2 role in nuclear-mitochondria communication, these findings reveal an exquisite regulatory network for modulating mitochondrial gene expression through spatially coordinated transcription and translation.

INTRODUCTION

Maintenance of mitochondria metabolism and energy homeostasis is guaranteed by a constant turnover of the mitochondrial network, including both generation of new mitochondria, remodeling of existing mitochondria and removal of damaged organelles[1]. Mitochondria biogenesis and rewiring of mitochondrial functions require coordinated gene expression from the mitochondrial and nuclear genomes[2–5]. This is achieved through energy-sensing signaling pathways impacting on the transcriptional network controlling the expression of nuclear-encoded mitochondrial genes, and via shuttling of transcription factors and cofactors between the two organelles[6–9]. In yeast, balanced expression of different OXPHOS subunits is also facilitated by synchronized control of mitochondrial and cytosolic translation[2,10–13], suggesting that coordinated regulation of multiple levels of gene expression may be required for the maintenance of mitochondrial homeostasis. However, the molecular mechanisms promoting balanced mitochondrial gene expression and specific mRNA processing and translation at the level of single organelles in mammals are not yet fully understood. Recent studies have identified RNA-binding proteins responsible for recruiting selected mRNAs to the mitochondrial outer membrane surface[14–23], providing some clues to the specificity of translation on mitochondria-associated ribosomes as compared to cytosolic ribosomes. However a complete understanding of the modes of regulation of mitochondria-associated translation is currently lacking.

Ubiquitination is a reversible protein post-translational modification that is achieved through the sequential actions of several classes of enzymes, including a ubiquitin (Ub)-activating enzyme (E1), a Ub-conjugating enzyme (E2), and a Ub ligase (E3), that work together to mediate the attachment of one or multiple ubiquitin moieties to lysine residues on target proteins[24,25]. In the case of poly-ubiquitination, chains of different topology can either promote protein degradation or serve, as in the case of other post-translational modifications, to influence protein functions and interactions[26,27]. Among others, K48-linked ubiquitin chains are best known as markers for

proteasomal degradation, whereas K63-linked ubiquitin chains are non-proteolytic[28,29] and are

associated with immune signaling, DNA damage repair, protein sorting, and translation[30–37].

Moreover, more recent studies point to a broader role in regulating cellular metabolism and

adaptive responses to stress[38–43]. Notably, K63-linked ubiquitin mediates translational regulation

in yeast exposed to oxidative stress[39,42].

We recently identified GPS2 as an inhibitor of K63 ubiquitination synthesized by the E2

conjugating enzyme Ubc13[44]. GPS2-mediated inhibition of K63 ubiquitination is essential for

promoting several coordinated functions across the cell, including the transcriptional regulation of

mitochondrial genes in the nucleus and activating insulin signaling and pro-inflammatory

pathways in the cytosol[9,44–47]. These complementary activities across different subcellular

compartments are facilitated by GPS2 translocation between organelles, making GPS2 an

excellent candidate for mediating the coordination of nuclear and extranuclear processes

contributing to the remodeling of cellular metabolism. Regulated mitochondria-to-nucleus

shuttling of GPS2, for example, controls mitochondria biogenesis via transcriptional activation of

nuclear-encoded mitochondrial genes[9]. Acting as a mediator of mitochondria retrograde

signaling, GPS2 is also required for licensing the expression of stress response genes upon

mitochondria depolarization[9]. Upon translocation to the nucleus, GPS2-mediated inhibition of K63

ubiquitination impacts the remodeling of the chromatin environment of target gene promoters by

stabilizing histone demethylases[9]. At the same time, its removal from the outer mitochondrial

membrane may release the ubiquitination of other targets, which are currently unknown. Here,

we have profiled the GPS2-regulated ubiquitome and dissected the role of GPS2-regulated K63

ubiquitination in modulating mitochondria-associated protein translation. Our results point to a

novel regulatory strategy whereby GPS2 provides a unifying strategy for coordinating the

transcriptional and translational control of mitochondrial gene expression by inhibiting K63

ubiquitination of key targets by the mitochondrial ubiquitin ligase Mul1.

RESULTS

Remodeling of the mitochondrial proteome in the absence of GPS2

Our previous work has identified GPS2 as a regulator of mitochondrial gene expression,

through transcriptional control of nuclear-encoded mitochondrial (neMITO) genes, and as a

mediator of mitochondria-to-nucleus retrograde signaling[9]. To further dissect the role of GPS2 in

regulating mitochondrial functions, we profiled the mitochondrial proteome and transcriptome of

immortalized mouse embryonic stem cells (MEFs) derived from either GPS2$^{fl/fl}$/Ubc^{ERT2}-Cre^{+} or

GPS2$^{fl/fl}$/Ubc^{ERT2}-Cre^{-} mice. Upon Tamoxifen treatment, GPS2 deletion is induced in Ubc^{ERT2}-Cre^{+}

cells (from here on called GPS2-KO), whereas Ubc^{ERT2}-Cre^{-} (from here on called WT) serve as

negative control (**Supplemental Figure S1A**). In agreement with previous studies in other cell

models, GPS2-KO MEFs present with severely reduced mitochondrial content compared to WT

cells (**Supplement Figure S1B**).

To achieve a comprehensive characterization of the changes associated with GPS2

deletion, we first profiled mitochondrial extracts from WT and KO MEFs using quantitative tandem

mass tag (TMT) labeling followed by quantification via mass spectrometry (LC-MS/MS). We

identified 891 differentially expressed proteins across three replicates (**Supplementary Table 1**,

P-value <0.05 and LogFC>0.25**)**. In accord with our previous findings in adipocytes and breast

cancer cells[44,46,47], upregulated proteins were enriched for pathways previously found to be

regulated by cytosolic GPS2, including EGFR/Insulin signaling, inflammatory responses, and

TNFalpha/MAPK signaling (**Supplemental Table 1** and **Figure S1C**). Downregulated proteins,

instead, spanned various mitochondrial functions, including Electron Transport Chain (ETC), fatty

acid oxidation, TCA cycle, and amino acid metabolism (**Supplemental Table 1** and **Figure S1C**).

Accordingly, filtered analysis of intrinsic mitochondrial proteins, based on the latest MitoCarta 3.0

database, indicated that the majority of differentially expressed mitochondrial proteins are

downregulated in GPS2-KO cells, as expected based on previous studies (**Figure 1A**)[9]. However,

we also identified a small subset of mitochondrial proteins upregulated in the absence of GPS2.

Interestingly, the upregulated program was enriched in proteins involved in antioxidant response

and programmed cell death (**Figure 1A**), which suggests adaptive changes in response to the

stress of GPS2 deletion. Upregulation of anti-oxidative protective proteins SOD2 and PRDX2,

fatty acid synthase FASN, and downregulation of pyruvate dehydrogenase PDHA and OXPHOS

proteins was confirmed by western blotting of mitochondrial extracts from GPS2 WT and KO

MEFs (**Figure 1B**).

To characterize the molecular mechanisms underlying the adaptive regulation of

mitochondrial gene expression in the absence of GPS2, we profiled mitochondria-associated RNA

from WT and GPS2-KO MEFs by RNA-seq. Among the differentially expressed genes (DEGs)

(**Supplementary Table 2**), we identified 316 mitochondrial genes consistently regulated across

three independent replicates, including 138 upregulated and 178 downregulated genes. Overlay

of the RNA-seq results over the proteomics data confirmed that the downregulation of

mitochondrial proteins observed in GPS2-KO cells is largely associated with reduced mRNA

levels (**Figure 1C**), as expected based on GPS2 acting as a required transcriptional cofactor for

the activation of neMITO genes[9]. Indeed, overlay of the MEFs proteomics data over GRO-seq

data previously generated in 3T3-L1 cells with acute GPS2 downregulation further indicates that

protein downregulation likely results from defective transcription (**Figure 1D**)[9]. Mitochondrial

proteins upregulated in GPS2-KO cells instead included genes presenting both increased (59%,

depicted in red in **Figure 1C**) or decreased (35%, depicted in blue in **Figure 1C**) mRNA

abundance in KO versus WT cells. However, a comparison of protein and nascent RNA

expression suggests that the transcription of the majority of proteins differentially regulated in

MEFs, including both up- and down-regulated genes, is impaired in the absence of GPS2 (**Figure**

1D). This suggests that multiple levels of regulation may be contributing to the remodeling of the

mitochondrial proteome of GPS2-KO cells, including both transcriptional repression and post-

transcriptional regulation of mRNA stability and/or protein synthesis, with the outcome for different

gene/protein sets depending on the overlay of these complementary regulatory strategies.

GPS2 restricts K63 ubiquitination of mitochondrial proteins

149   To further our understanding of the adaptive rewiring of the mitochondrial proteome in

GPS2-null cells, we decided to investigate the mechanism/s responsible for post-transcriptional

regulation of mitochondrial gene expression in the absence of GPS2. Because our previous work

indicates that GPS2 exerts its functions across different subcellular compartments via inhibition

of the ubiquitin-conjugating enzyme Ubc13[9,44–48], we focused on K63 ubiquitination as a possible

regulatory mechanism. First, we asked whether loss of GPS2 leads to unrestricted K63

ubiquitination activity on mitochondria. Indeed, we observed increased accumulation of K63

ubiquitin chains in mitochondrial extract from GPS2 KO cells compared to the WT line by western

blot analysis (**Figure 2A**). To identify putative targets of GPS2-mediated regulation, we then

profiled the K63 ubiquitome of GPS2 WT and KO MEFs by LC-MS/MS. Relative quantification

was performed by stable isotope labeling of amino acid in cell culture (SILAC) (**Figure 2B**), with

K63 ubiquitinated proteins being enriched prior to mass spectrometry through selective binding

to the high-affinity lysine-63-poly-ubiquitin binding domain Vx3K0[49] (**Supplemental Figure 2A**

and **2B**). This approach led to the identification of 73 candidate targets, among 230 differentially

enriched proteins, for which the increase in the H/L ratio indicated increased ubiquitination and/or

increased interaction with ubiquitinated targets in GPS2-KO cells (**Supplemental Figure 2C** and

Supplemental Table 3). Unexpectedly, we found that putative targets of GPS2-mediated

regulation were strongly enriched for factors involved in protein translation (**Figure 2C**), whereas

no significant overlap with known targets of K63 ubiquitination by Parkin was observed, despite

mitophagy markers being activated in GPS2-KO cells (Supplemental Figure 2D, 2E and

Supplemental Table 3). These findings were confirmed when profiling was repeated using TMT

labeling instead of SILAC (**Supplemental Figure 2D**). A similar enrichment in proteins involved

in translation and RNA processing was also observed by profiling the K63 ubiquitome of MDA-

MB231 breast cancer cells deleted of GPS2 (REF) (**Supplemental Figure 2E** and **Supplemental**

Table 3). Moreover, the increased ubiquitination of representative translation factors RPS11 and

RACK1 - both previously reported as direct targets of non-proteolytic ubiquitination (REFs) - was

confirmed by IP/WB using both whole-cell extracts and fractionated mitochondrial extracts

(**Figure 2D**). This indicates that lack of GPS2 promotes exacerbated ubiquitination of translation

factors associated with mitochondria, thus suggesting that GPS2-mediated inhibition of K63

ubiquitination might regulate mitochondria-associated protein translation.

To investigate whether protein translation is regulated in absence of GPS2, we compared

the rate of protein translation in WT and KO cells by monitoring the incorporation of puromycin

into newly synthesized proteins across subcellular compartments. A significant increase in

puromycin incorporation was observed in mitochondria from GPS2-KO cells compared to WT

(**Figure 2E**). Pre-treatment of cells with the translation initiation inhibitor homoharringtonine

(HHT)[50] reduced puromycin incorporation in both WT and KO mitochondria, indicative of active

translation. Remarkably, the increase in puromycin incorporation was specific to the mitochondrial

compartment, with no significant changes observed in nuclear and cytosolic extracts (**Figure 2E**).

Together, these results indicate that the rate of protein translation in mitochondrial extracts is

specifically upregulated in absence of GPS2. Based on previous studies indicating that this

approach allows for selective measurement of translation of nuclear-encoded mitochondrial

proteins occurring on the outer mitochondrial membrane (OMM) as compared to the translation

of mitochondria-encoded genes[51], we concluded that mitochondria-associated translation of

neMITO genes increases in absence of GPS2. This suggests a localized regulatory strategy

impacting mRNAs translated by ribosomes docked on the mitochondria rather than free cytosolic

ribosomes. In accord with this hypothesis, we observed that transcripts encoding for more than

half of the upregulated proteins in GPS2-KO cells are recruited to the outer mitochondrial

membrane for import-coupled translation via interaction with the AKAP1/MDI/LARP

complex[18,52](**Supplementary Table 1**). Conversely, no significant overlap was observed between

upregulated proteins in the absence of GPS2 and transcripts binding to CluH, an RNA binding

protein responsible for the assembly of cytosolic granules promoting the translation of a variety

of mitochondrial proteins[14,15,53], including several showing reduced transcription in the absence of

GPS2 (**Supplementary Table 1**). Together, these comparative *in silico* analyses suggest that

enhanced translation of mitochondrial proteins in the absence of GPS2 is specific for

mitochondrial transcripts translated by mitochondria-associated ribosomes.

PABPC1 ubiquitination by Mul1

To gain further mechanistic insights into the regulation of mitochondria protein translation via K63

ubiquitination, we focused on the poly-A binding protein PABPC1. PABPC1 is not only a known

target of ubiquitination[54] but also the single putative target of GPS2 regulation identified across

different multiple experimental setups (SILAC and TMT labeling) and different cell types (MEFs

and MDA-MB-231) (**Supplemental Figure 3A**). Two complementary IP/WB approaches

confirmed increased K63 ubiquitination of PABPC1 in the mitochondria of GPS2-KO cells. In the

first assay, we immunoprecipitated K63Ub-containing proteins by binding to the Vx3KO trap and

visualized PABPC1 by WB (**Figure 3A**). In the second, we immunoprecipitated PABPC1 and

visualized associated K63Ub chains by WB (**Figure 3B**). As expected, the increase in high

molecular weight (HMW) Ub chains observed in GPS2-KO cells was reversed by inhibiting the

activity of ubiquitin-conjugating enzyme Ubc13 with the chemical inhibitor NSC697923

(REF)(**Figure 3B**). A Ubc13-dependent increase in PABPC1 ubiquitination was also observed

upon depolarization of mitochondria by FCCP, a condition mimicking GPS2 downregulation

through its relocalization from mitochondria to the nucleus[9](**Figure 3C**). Unexpectedly, this

experiment revealed that FCCP-induced ubiquitination of PABPC1 depended on the mitochondria

specific E3 ligase MUL1 rather than MKRN1, which had been previously associated with PABPC1

ubiquitination in the cytosol (**Figure 3C**). Ubiquitination of PABPC1 by MUL1 and Ubc13, as

recapitulated *in vitro* using bacterially expressed recombinant proteins, was significantly reduced

upon mutagenesis of the previously identified ubiquitination sites (K78, K188, K284, and K512)

(**Figure 3D**) and significantly inhibited by GPS2 (**Figure 3E**). Together these results indicate that

PABPC1 can be locally regulated through different ubiquitination machineries and that GPS2 is

specifically responsible for preventing its ubiquitination by Mul1 on mitochondria.

PABPC1 is an RNA-binding protein and a key component of the translation machinery. PABPC1

concomitant interactions with the polyA-containing 3'UTR and 5' Cap-bound components of the

translation initiation complex promote protein translation through closed-loop mRNP

formation[55,56]. To unravel whether loss of GPS2 may be impacting on mitochondria-associated

translation through aberrant PABPC1 ubiquitination, we first asked whether PABPC1 interaction

with the translation initiation complex is altered in the absence of GPS2. Co-immunoprecipation

experiments indicated that PABPC1 interaction with the translation initiation factor eIF4G and

translational activator PABP-interacting protein 1 (PAIP1) is more robust in mitochondria from

GPS2-KO cell than their WT counterparts (**Figure 3F)**. In contrast, interaction with the

translational repressor PABP-interacting protein 2 (PAIP2), which competes with PAIP1 for

interaction with PABP[57], is significantly decreased (**Figure 3F)**. These changes are rescued by

transient downregulation of the E3 ubiquitin ligase MUL1 (**Figure 3G**), indicating that aberrant

ubiquitination of MUL1 target/s in the absence of GPS2-mediated inhibition of Ubc13 activity is

indeed a contributing factor to the observed phenotype. This conclusion was further confirmed by

rescue of enhanced protein translation rate in GPS2-KO MEF cells through MUL1 downregulation

by siRNA, as measured by mitochondrial puromycilation assay (**Figure 3H**).

While we have primarily focused on PABPC1 due to its striking identification across multiple

datasets, we also considered the possibility that ubiquitination of additional factors may be

contributing to regulate mitochondria-associated translation. GPS2-regulated K63 ubiquitome

included a number or putative targets involved in RNA processing and translation. Among them,

eukaryotic translation initiation factor 3, subunit M (eiF3m), was also confirmed as a direct target

of GPS2/Ubc13/Mul1-mediated regulation (**Supplemental Figure 3B**). Our results together

indicate that GPS2 regulates mitochondria-associated translation by preventing aberrant MUL1-

mediated ubiquitination of translation factors like PABPC1 and eIF3m on the outer mitochondrial

membrane.

K63ub-mediated regulation of mitochondria-associated translation in stress response

Our previous studies indicate that, in conditions of mitochondrial depolarization, GPS2

translocates to the nucleus for regulating the transcription of stress response genes[9]. This

suggested that removal of GPS2 by translocation could have the indirect effect of releasing Mul1

activity and promoting mitochondrial protein translation as part of the adaptive stress response.

To investigate this possibility, we first assessed the ubiquitination of PABPC1 after depolarization

with FCCP for 10' or 30'. As expected, concomitant to the translocation of GPS2 from

mitochondria to the nucleus (**Figure 4A**), we observed a significant increase in mitochondria-

associated K63 poly-ubiquitination of PABPC1 (**Figure 4B** and **4C**). Under these conditions,

PABPC1 interaction with the translation initiation complex is strengthened (**Figure 4D**). This

correlates with the activation of a gene expression program that, in part, mirrors that identified in

response to GPS2 deletion (**Figure 4E, bottom cluster**), as validated by western blotting for

antioxidant proteins SOD2 (**Figure 4F**). At the same time, activation of a large part of the FCCP-

induced program is impaired in GPS2-KO cells, likely due to reduced transcription in the absence

of nuclear GPS2.

DISCUSSION

Previous studies have characterized GPS2 as a mediator of mitochondria retrograde signaling, a

transcriptional cofactor involved in mediating both gene repression and activation, and an inhibitor

of non-proteolytic K63 ubiquitination. Together, these complementary functions ensure a proper

adaptive response to mitochondrial stress and regulate mitochondria biogenesis during

differentiation, with GSP2 translocating from mitochondria to nucleus to regulate nuclear-encoded

mitochondrial genes transcription via stabilization of chromatin remodeling enzymes[9]. A key

implication of these findings is that restricted K63 ubiquitination in the nucleus indirectly regulates

mitochondrial functions through the expression of stress response and nuclear-encoded

mitochondrial genes. However, it remains unclear whether GPS2 also contributes to the

regulation of mitochondria homeostasis in a direct manner, possibly by modulating the

ubiquitination of mitochondrial proteins. To address this question, we have profiled the GPS2-

regulated K63 ubiquitome in mouse embryonic fibroblasts and human breast cancer cells. To our

surprise, we did not observe any significant overlap between the GPS2-regulated program and

the mitochondrial proteins targeted by Parkin-mediated ubiquitination. This suggests that stress-

induced translocation of GPS2 is unlikely to contribute to removing defective mitochondria via

mitophagy. Instead, GPS2-mediated inhibition of K63 ubiquitination prevalently affects proteins

involved in RNA processing and translation. In particular, our results indicate that GPS2-mediated

inhibition of K63 ubiquitination contributes to regulating the mitochondria-associated translation

of a specific of nuclear-encoded mitochondrial genes. Together with the previous characterization

of nuclear GPS2 as an essential cofactor for the expression of nuclear-encoded mitochondrial

genes, these findings indicate that GPS2-mediated inhibition of K63 ubiquitination represents a

unifying strategy for modulating the expression of mitochondrial proteins through coordinated

transcription and translation events.

Mitochondrial proteins regulated through this strategy are enriched for factors involved in the

antioxidant response, which is consistent with both the role played by GPS2 in mediating the

mitochondrial stress response and the role played by K63 ubiquitination in regulating ribosomal

activity in yeast (REF). Recent studies have identified RNA binding proteins, such as Puf3p in

yeast, Clu and MDI/Larp in flies, CluH and dAKAP1/LARP4 in mammalian cells, that are involved

in the selective regulation of different subsets of nuclear-encoded mitochondrial

proteins[14,17,18,52,58–62]. Mitochondrial proteins upregulated in GPS2-KO cells present a significant

overlap with the AKAP1/MDI/LARP complex targets, which is responsible for recruiting mRNAs

to the outer mitochondrial membrane for import-coupled translation. In contrast, no overlap was

observed with transcripts binding to CLUH, an RNA binding protein responsible for the assembly

of cytosolic granules promoting the cytosolic synthesis of various mitochondrial proteins. These

results suggest that different sets of nuclear-encoded mitochondrial genes might be regulated

through independent strategies, with GPS2-controlled K63 ubiquitination being restricted to the

local regulation of mitochondria-associated translation. This separation is likely to be critical for

ensuring the maintenance of mitochondrial and cellular homeostasis.

Mechanistically, our results indicate that GPS2 regulates mitochondrial-associated translation by

inhibiting the ubiquitination of the RNA binding protein PABPC1 and other translation factors by

the mitochondrial E3 ubiquitin ligase Mul1. To our surprise, our data point to the mitochondria-

specific Mul1 as the E3 ligase regulating PABPC1 ubiquitination both *in vivo* and *in vitro*, rather

than MKRN1, which had been previously associated with the ubiquitination of PABPC1 in

HEK293T[54]. Mul1 is a dual function E3 ligase promoting either the ubiquitination or SUMOylation

of mitochondrial targets[63,64]. Previous studies have described an important role for Mul1 in

regulating a variety of physiological and pathological processes, including mitochondrial

dynamics, cell growth, apoptosis, and mitophagy[65–69]. Our study adds to this body of work by

showing that Mul1-mediated ubiquitination regulates the activity of translation factors localized to

the OMM and restricts the local translation of a subset of nuclear-encoded mitochondrial proteins.

One intriguing aspect of Mul1 involvement in regulating mitochondria-associated translation is

that it is uniquely suited for playing a key role in the mitochondrial stress response (MSR).

Because of its spatial organization, Mul1 can in fact sense mitochondrial stress in the

intermembrane mitochondrial space and respond through the ubiquitination of specific substrates

on the outer mitochondrial surface[68–70]. Our data support this possibility as we observed increased

ubiquitination of PABPC1 upon mitochondrial depolarization, concomitant to GPS2 retrograde

translocation to the nucleus.

The relationship between GPS2 and Mul1 in mitochondria appears quite complex. Mul1 was

previously shown to regulate the sumoylation of GPS2, as required for regulating GPS2

intracellular localization and translocation in stress conditions[9]. At the same time, results

presented here indicate that GPS2 inhibits Ubc13/Mul1-mediated ubiquitination of PABPC1, likely

through inhibition of Ubc13 activity. Together, these observations suggest a complex regulatory

strategy for modulating mitochondrial adaptation to stress which includes: 1) Mul1-mediated

sumoylation of GPS2 is removed by SENP1; 2) desumoylation favors GPS2 translocation to the

nucleus where it promotes the transcription of stress response and nuclear-encoded

mitochondrial genes; 3) at the same time the absence of GPS2 in mitochondria licenses

Mul1/Ubc13 activity on mitochondria-associated translation factors, in turn enhancing the

translation of antioxidant proteins to promote adaptation to the mitochondrial stress.

While we have mainly focused on PABPC1 as a key target of GPS2-regulated ubiquitination in

this study, our proteomics data suggest that PABPC1 is not the only target relevant to the

regulation of mitochondrial-associated translation. Ribosomes are known to be regulated by non-

proteolytic ubiquitination as well, and ribosomal subunit RPS11 and scaffold factor RACK1[71–73].

In addition, we identified Eif3m, a translation initiation factor, as a target of GPS2-regulated K63

ubiquitination and GPS2. These results suggest that regulation of mitochondrial-associated

translation is achieved by the concomitant ubiquitination of multiple factors working together.

Further studies will be required to dissect the specific sites of ubiquitination and the contribution

of individual PTM events.

In conclusion, our work indicates that GPS2 plays an important role in mitochondrial regulation

by inhibiting ubiquitin signaling. Together with the recent characterization of GPS2-mediated

regulation of nuclear-encoded mitochondrial genes transcription, our results add to the

significance of the GPS2 role in integrating multiple layers regulating cell growth, metabolism, and

stress resistance.

ACKNOWLEDGMENTS

We thank all past and present members of the Perissi Lab for their continuous support and

encouragement. We are grateful to Drs. Christine Vogel and Gustavo Silva for their assistance

with protocols for the enrichment of K63 ubiquitinated proteins. Genomic profiling experiments

have been run by the Boston University Microarray & Sequencing Resource Core. This work was

supported by NIH and Department of Defense grant awards as follows: NIGMS R01GM127625

to VP, DoD W81XWH-17-1-0048 to VP, R00GM124458 to SML

 Materials and Methods

 Reagents and antibodies

Anti-GPS2 antibody was generated in rabbit against a peptide representing aa 307-327.

Commercial antibodies used were as follows: anti-ubiquitin (P4D1 clone, Cell Signaling

Technology), anti-β-tubulin (TUB 2.1 clone, Sigma), anti-HDAC2 (ab16032, Abcam), anti-

mtHSP70 (catalog no. MA3-028, Invitrogen), anti-K63 (catalog no. 05-1308, Millipore), anti-α-

Tubulin (catalog no. T5168, Sigma), anti-GAPDH (catalog no. MA5-15738, Invitrogen), anti-

PABPC1 (ab21060, Abcam), anti-RPS11(NBP2-22289, Novus Biologicals), anti-Rack1 (sc-

17754, Santa Cruz Biotechnology), anti-Eif4G (15704-1-AP, Proteintech), anti-Paip1 (sc-365687,

Santa Cruz Biotechnology), anti-Paip2 (15583-1-AP, proteintech), anti-Flag-HRP (catalog no.

a8592, Sigma), anti-Puromycin (clone 12D10, Millipore), anti-PDHA (ab168379, Abcam), anti-

Oxphos (ab110413, Abcam), anti-SOD2 (sc-137254, Santa Cruz Biotechnology). siRNAs against

mouse GPS2, UBC13, MKRN1, MUL1, and UBC9 were purchased from Ambion. Nonspecific

scrambled siRNA was included as negative controls in each experiment.

 Cell culture

Standard molecular cloning, cell culture, and cell transfection experiments were performed as

described by J. Sambrook, D. W. Russell, Molecular Cloning: A Laboratory Manual (Cold Spring

Harbor Laboratory Press, Cold Spring Harbor, N.Y., ed. 3rd, 2001). For cells transfection,

jetPRIME was used following the manufacturer's protocol (Polyplus transfection). Immunostaining

was performed following standard protocols on cells fixed in 4% paraformaldehyde in PBS, using

Alexa Fluor-conjugated secondary antibodies (Molecular probes).

Mouse embryonic fibroblasts (MEFs) cells were maintained in DMEM with 4.5 g/L glucose and L-

glutamine and 10% FBS at 37°C and 5% CO_2. Conditional Gps2$^{flox/flox}$ mice were generated by

inGenious Targeting Laboratory. Wild-type mice used as control for all analyses presented here

were littermates Gps2$^{flox/flox/}$CD19Cre^{-}.

MDA-MB-231 breast cancer cells were grown in DMEM with 4.5 g/L glucose and L-glutamine and

10% FBS at 37°C and 5% CO_2. MB231 GPS2 KO cells were generated and described

previously[47].

Protein extraction, subcellular fractionation, immunoprecipitation and western blotting

For whole cell extraction, cultured cells were pelleted and incubated for 20 minutes on ice in IPH

buffer (50 mM Tris HCl [pH 8.0], 250 mM NaCl, 5 mM EDTA, 0.5% NP-40, 0.1mM PMSF, 2mM

Na3VO4, 50mM NaF, and 1X protease inhibitors (Sigma Aldrich)). For cytoplasmatic,

mitochondrial and nuclear extracts fractionation, cells were pelleted and resuspended in gradient

buffer (10 mM HEPES [pH 7.9], 1mM EDTA, 210 mM Mannitol, 70mM Sucrose, 10mM NEM, 50

mM NaF, 2 mM Na2VO3, 1mM PMSF and 1x protease inhibitor mixture), then homogenized by

syringe followed by low-speed centrifugation for 10 min. The supernatant containing cytosolic

proteins was recovered and subjected to high-speed centrifugation to separate the mitochondrial

pellet from the cytoplasmic fraction, and the nuclear pellet was lysed for 20 min in high-salt buffer

(20 mM Tris-HCL [pH 8.0], 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM

DTT, 10mM NEM, 50 mM NaF, 2 mM Na3VO4, 1mM PMSF and protease inhibitor mixture). The

mitochondrial pellet was incubated for 15 min in lysis buffer (50 mM Tris/HCl [pH 8.0], 300 mM

NaCl, 1mM EDTA, 1% Triton X-100, 10mM NEM, 50 mM NaF, 2 mM Na2VO3, 1mM PMSF and

protease inhibitor mixture). The concentration of protein extracts was measured using the

Bradford assay (Bio-Rad). Extracts were boiled in SDS sample buffer and loaded directly on

precast Bio-Rad gels. For immunoprecipitation, protein extracts were incubated with the specific

antibody overnight at 4 °C after adjusting the buffer to a final concentration of 150 mM NaCl and

0.5% NP-40 and then incubated for 1 h with Protein A-Sepharose™ 4B (Invitrogen), washed

extensively, separated by electrophoresis, transferred onto PVDF membranes (Millipore), and

subjected to Western blotting following standard protocols.

Recombinant Protein Expression

cDNAs encoding the tandem ubiquitin-binding entity (Vx3K0 and Rx3(A7)) (Sims J., 2012, Nature

protocol) were subcloned into pET28a-His-tag expression vector. Human clone of GPS2 and

mouse clone of PABPC1 and mutated PABPC1 (with four lysine mutations: K78R, K188R, K284R

and K512R) were subcloned into pET-32a-His-tag expression vectors. His-tagged Vx3K0,

Rx3(A7), GPS2 and PABPC1 were produced as a His-tag fusion protein in BL21 *Escherichia coli*,

resin-purified on nickel-nitrilotriacetic acid beads, and eluted accordingly to manufacturer's

protocol (Life Technologies). The His-Vx3K0/Rx3(A7)-conjugated agarose were stored at 4°C in

PBS supplemented with 30% glycine.

Immunochemical methods

For pull-down of K63-ubiquitylated proteins, cells were lysed in high-stringency buffer (50 mM

Tris, pH 7.5; 500 mM NaCl; 5 mM EDTA; 1% NP40; 1 mM dithiothreitol (DTT); 0.1% SDS)

containing 1.25 mg ml−1 N-ethylmaleimide, 0.1% PMSF, and protease inhibitor cocktail (Roche).

His-Vx3K0/Rx3(A7) were added to immobilize the K63-ubiquitylated proteins, and bound material

was washed extensively in high-stringency buffer four times. Proteins were resolved by SDS-

APGE and analyzed by immunoblotting.

In vitro ubiquitination assay

Ubiquitination assays were carried out at 30°C for 2h in 50mM Tris-HCl, pH7.6, containing 50mM

NaCl, 5mM MgCl2, 5mM ATP, 1x Ubiquitin Aldheide, 50nM E1, 5µg ubiquitin, 200 nM UbcH13–

Uev1a E2 complexes (Boston Biochem), 0.1ug recombinant human MUL1 Protein (H00079594-

P01, Novus Biologicals). Bacterial expressed His-PABPC1/mutated PABPC1 was used as
substrate.

<u>**Mitochondrial RNA Isolation and RNA-seq**</u>

Mitochondrial RNA was isolated from isolated mitochondrial pellet following the manufacturer
protocol for the RNeasy Kit (QIAGEN). Isolated mitochondrial RNA was subjected to quality
control on Agilent Bioanalyzer and RNA library preparation following Illumina's RNA-seq Sample
Preparation Protocol. Resulting cDNA libraries were sequenced on the Illumina's HiSeq 2000.

<u>**Mitochondrial Content**</u>

Total DNA was extracted from cells using QuickExtract DNA Extraction Solution 1.0 (Epicenter)
following manufacturer's instructions. DNA amplification of the mitochondrial-encoded NADH
dehydrogenase 1 (mt-ND1) relative to nuclear TFAM was used to determine mitochondrial DNA
copy number.

<u>**Translation activity**</u>

Puromycin incorporation into newly synthesized proteins was performed to measure translation
activity. MEFs WT and GPS2-KO cells were treated in the presence or absence of
homoharringtonine (HHT) (5 µM, Tocris Bioscience) for 10 min to prevent new translation
initiation, prior to an additional 5 min incubation with puromycin (100 µM, Sigma) and emetine
(200 µM, Sigma) at 37°C. Cells were collected by centrifugation, and lysate was prepared as
described above. Thirty micrograms of protein were loaded onto a 10% SDS-PAGE gel for
immunoblotting analysis.

 Sample preparation for MS analysis

For mitochondrial proteome profiling, mitochondrial proteins from MEFs WT and GPS2-KO cells

were isolated as described before[9]. An equal amount of solubilized mitochondrial proteins from

different samples were separated by SDS-PAGE and then digested in-gel by trypsin overnight

using standard methods[74].

For SILAC-K63 experiments, MEFs WT and GPS2-KO cells or MDA-MB231 WT and GPS2-KO

cells were grown in medium containing native (unlabeled) L-arginine and L-lysine (Arg0/Lys0) as

the light condition, or stable isotope-labelled variants of L-arginine and L-lysine (Arg10/Lys8) as

the heavy condition[75]. Proteins from whole cellular lysates were extracted from SILAC-labelled

MEFs WT and GPS2-KO cells or MDA-MB-231WT and GPS2-KO cells as described before. An

equal amount of proteins from the two SILAC states was mixed and precipitated by His-Vx3K0-

conjugated agarose and incubating at 4°C for 1h. Precipitated proteins were eluted with SDS

sample buffer, incubated with 10 mM DTT for 10min at 100 °C. Proteins were separated by SDS-

PAGE and then digested in-gel by trypsin overnight using standard methods. The resulting

peptides were desalted using reverse phase (C18) Tips (Thermo Scientific) per the

manufacturer's instructions.

For TMT based-K63 experiments, MEFs WT and GPS2-KO cells were grown in normal medium

to 80% confluency. After lysis with IPH buffer, protein quantities from whole cellular lysates were

determined using the Bradford assay. An equal amount of proteins from MEFs WT or GPS2-KO

cells was precipitated by His-Vx3K0-conjugated agarose and incubating at 4°C for 1h.

Precipitated proteins were eluted with SDS sample buffer, incubated with 10 mM DTT for 10min

at 100 °C. Proteins were separated by SDS-PAGE and then digested in-gel by trypsin overnight

using standard methods. The resulting peptides were desalted using C18 Tips (Thermo Scientific)

per the manufacturer's instructions and vacuum-dried. The dried peptides were redissolved in 0.5

M TEAB, and processed independently according to the manufacturer's protocol for a 10-plex

Tandem Mass Tag (TMT) reagent labeling kit (Thermo Fisher Scientific). The different TMT-

labeled peptide mixtures were pooled equally, desalted and dried by vacuum centrifugation.

Mass spectrometric analysis

Peptides were analyzed on a Q-Exactive HF mass spectrometer (QE-HF, Thermo Fisher

Scientific) equipped with a nanoflow EasyLC1200 HPLC system (Thermo Fisher Scientific).

Peptides were loaded onto a C18 trap column (3 µm, 75 µm × 2 cm, Thermo Fisher Scientific)

connected in-line to a C18 analytical column (2 µm, 75 µm × 50 cm, Thermo EasySpray) using

the Thermo EasyLC 1200 system with the column oven set to 55 °C. The nanoflow gradient

consisted of buffer A (composed of 2% (v/v) ACN with 0.1% formic acid) and buffer B (consisting

of 80% (v/v) ACN with 0.1% formic acid). For protein analysis, nLC was performed for 180 min at

a flow rate of 250 nL/min, with a gradient of 2-8% B for 5 min, followed by a 8-20% B for 96 min,

a 20-35% gradient for 56min, and a 35-98% B gradient for 3 min, 98% buffer B for 3 min, 100-0%

gradient of B for 3 min, and finishing with 5% B for 14 min. Peptides were directly ionized using a

nanospray ion source and analyzed on the Q-Exactive HF mass spectrometer (Thermo Fisher

Scientific).

QE-HF was run using data dependent MS2 scan mode, with the top 10 most intense precursor

ions acquired per profile mode full-scan precursor mass spectrum subject to HCD fragmentation.

Full MS spectra were collected at a resolution of 120,000 with an AGC of 3e6 or maximum

injection time of 60 ms and a scan range of 350 to 1650 m/z, while the MS2 scans were performed

at 45,000 resolution, with an ion-packet setting of 2e4 for AGC, maximum injection time of 90 ms,

and using 33% NCE. Source ionization parameters were optimized with the spray voltage at 2.1

kV, transfer temperature at 275 °C. Dynamic exclusion was set to 40 seconds.

Data analysis

All acquired MS/MS spectra were searched against the Uniprot mouse complete proteome FASTA database released on 2013_07_01, using the MaxQuant software (Version 1.6.7.0) that integrates the Andromeda search engine. Enzyme specificity was set to trypsin and up to two missed cleavages were allowed. Cysteine carbamidomethylation was specified as a fixed modification. Methionine oxidation, N-terminal acetylation, and lysine ubiquitination were included as variable modifications. Peptide precursor ions were searched with a maximum mass deviation of 6 ppm and fragment ions with a maximum mass deviation of 20 ppm. Peptide and protein identifications were filtered at 1% FDR using the target-decoy database search strategy. Proteins that could not be differentiated based on MS/MS spectra alone were grouped to protein groups (default MaxQuant settings). For mitochondrial protein annotation, we utilized the latest Mitocarta dataset(https://www.broadinstitute.org/files/shared/metabolism/mitocarta/human.mitocarta3.0.html).

Statistical analysis

The statistical data are from three independent experiments. Results are shown as mean ± SEM unless mentioned otherwise. Statistical analysis was performed by the Student's t-test for TMT-based quantification and RNA-seq data.

REFERENCES

1. Palikaras, K. & Tavernarakis, N. Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis. *Experimental Gerontology* **56**, 182–188 (2014).

2. RS, I., E, M. & LS, C. The Multiple Levels of Mitonuclear Coregulation. *Annual review of genetics* **52**, 511–533 (2018).

3. Quirós, P. M., Mottis, A. & Auwerx, J. Mitonuclear communication in homeostasis and stress. *Nature Reviews Molecular Cell Biology* **17**, 213–226 (2016).

4. English, J., Son, J. M., Cardamone, M. D., Lee, C. & Perissi, V. Decoding the Rosetta Stone of Mitonuclear Communication. *Pharmacological Research* 105161 (2020) doi:10.1016/j.phrs.2020.105161.

5. Woodson, J. D. & Chory, J. Coordination of gene expression between organellar and nuclear genomes. *Nature Reviews Genetics* vol. 9 383–395 (2008).

6. AM, N., MW, P., CJ, F., BM, B. & CM, H. Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation. *Science (New York, N.Y.)* **337**, 587–590 (2012).

7. CJ, F. *et al.* The Transcription Factor ATF5 Mediates a Mammalian Mitochondrial UPR. *Current biology : CB* **26**, 2037–2043 (2016).

8. S, A. *et al.* MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. *Mitochondrion* **20**, 43–51 (2015).

9. Cardamone, M. D. *et al.* Mitochondrial Retrograde Signaling in Mammals Is Mediated by the Transcriptional Cofactor GPS2 via Direct Mitochondria-to-Nucleus Translocation. *Molecular Cell* **69**, 757-772.e7 (2018).

10. MT, C., IC, S., G, S. & LS, C. Synchronized mitochondrial and cytosolic translation programs. *Nature* **533**, 499–503 (2016).

11. Margeot, A. & al., et. Why are many mRNAs translated to the vicinity of mitochondria: a role in protein complex assembly? *Gene* **354**, 64–71 (2005).

12. Chacinska, A. & al., et. Importing mitochondrial proteins: machineries and mechanisms. *Cell* **138**, 628–644 (2009).

13. Bykov, Y. S., Rapaport, D., Herrmann, J. M. & Schuldiner, M. Cytosolic Events in the Biogenesis of Mitochondrial Proteins. *Trends in Biochemical Sciences* **45**, 650–667 (2020).

14. J, G. *et al.* CLUH regulates mitochondrial biogenesis by binding mRNAs of nuclear-encoded mitochondrial proteins. *The Journal of cell biology* **207**, 213–223 (2014).

15. Schatton, D. *et al.* CLUH regulates mitochondrial metabolism by controlling translation and decay of target mRNAs. *The Journal of cell biology* **216**, 675–693 (2017).

561 16. Pla-Martín, D. *et al.* CLUH granules coordinate translation of mitochondrial proteins with
562   mTORC1 signaling and mitophagy. *The EMBO Journal* **39**, (2020).

563 17. Schatton, D. & Rugarli, E. I. A concert of RNA-binding proteins coordinates mitochondrial
564   function. *Critical Reviews in Biochemistry and Molecular Biology* **53**, 652–666 (2018).

565 18. Y, Z., Y, C., M, G. & H, X. The mitochondrial outer membrane protein MDI promotes local
566   protein synthesis and mtDNA replication. *The EMBO journal* **35**, 1045–1057 (2016).

567 19. A, S. & RT, C. Clueless is a conserved ribonucleoprotein that binds the ribosome at the
568   mitochondrial outer membrane. *Biology open* **5**, 195–203 (2016).

569 20. LJ, G.-R., AC, G. & LA, P. Puf3p, a Pumilio family RNA binding protein, localizes to
570   mitochondria and regulates mitochondrial biogenesis and motility in budding yeast. *The*
571   *Journal of cell biology* **176**, 197–207 (2007).

572 21. García-Rodríguez, L. J. & al., et. Puf3p, a Pumilio family RNA binding protein, localizes to
573   mitochondria and regulates mitochondrial biogenesis and motility in budding yeast. *J. Cell*
574   *Biol.* **176**, 197–207 (2007).

575 22. Garcia, M. & al., et. Mitochondria-associated yeast mRNAs and the biogenesis of
576   molecular complexes. *Mol. Biol. Cell* **18**, 362–368 (2006).

577 23. Williams, C. C. & al., et. Targeting and plasticity of mitochondrial proteins revealed by
578   proximity-specific ribosome profiling. *Science* **346**, 748–751 (2014).

579 24. CM, P. Mechanisms underlying ubiquitination. *Annual review of biochemistry* **70**, 503–
580   533 (2001).

581 25. CE, B. & C, W. New insights into ubiquitin E3 ligase mechanism. *Nature structural &*
582   *molecular biology* **21**, 301–307 (2014).

583 26. Kravtsova-Ivantsiv, Y. & Ciechanover, A. Non-canonical ubiquitin-based signals for
584   proteasomal degradation. *Journal of Cell Science* **125**, 539–548 (2012).

585 27. M, A., I, D. & A, B. Ubiquitin chain diversity at a glance. *Journal of cell science* **129**, 875–
586   880 (2016).

587 28. F, I., N, C. & I, D. What determines the specificity and outcomes of ubiquitin signaling?
588   *Cell* **143**, 677–681 (2010).

589 29. Chen, Z. J. & Sun, L. J. Nonproteolytic Functions of Ubiquitin in Cell Signaling. *Molecular*
590   *Cell* **33**, 275–286 (2009).

591 30. Mukhopadhyay, D. & Riezman, H. Proteasome-independent functions of ubiquitin in
592   endocytosis and signaling. *Science* **315**, 201–205 (2007).

593 31. J, S. *et al.* Cell cycle-regulated modification of the ribosome by a variant multiubiquitin
594   chain. *Cell* **102**, 67–76 (2000).

595   32.   F, H. *et al.* Lysine 63-linked polyubiquitination is required for EGF receptor degradation.
596   *Proceedings of the National Academy of Sciences of the United States of America* **110**,
597   15722–15727 (2013).

598   33.   E, L., C, J. & B, A. K63-linked ubiquitin chains as a specific signal for protein sorting into
599   the multivesicular body pathway. *The Journal of cell biology* **185**, 493–502 (2009).

600   34.   GS, S. *et al.* The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling
601   cascade at sites of DNA damage. *Cell* **136**, 420–434 (2009).

602   35.   C, D. *et al.* RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes
603   to allow accumulation of repair proteins. *Cell* **136**, 435–446 (2009).

604   36.   C, H., B, P., GL, M., G, P. & S, J. RAD6-dependent DNA repair is linked to modification of
605   PCNA by ubiquitin and SUMO. *Nature* **419**, 135–141 (2002).

606   37.   MU, G. *et al.* TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated
607   antiviral activity. *Nature* **446**, 916–920 (2007).

608   38.   IC, P. & W, S. Functional implications of K63-linked ubiquitination in the iron deficiency
609   response of Arabidopsis roots. *Frontiers in plant science* **4**, (2014).

610   39.   Dougherty, S. E., Maduka, A. O., Inada, T. & Silva, G. M. Expanding role of ubiquitin in
611   translational control. *International Journal of Molecular Sciences* **21**, (2020).

612   40.   Zhou, Y. *et al.* Structural impact of K63 ubiquitin on yeast translocating ribosomes under
613   oxidative stress. *Proceedings of the National Academy of Sciences of the United States*
614   *of America* **117**, 22157–22166 (2020).

615   41.   S, B., AW, G., C, V. & GM, S. Site-Specific K63 Ubiquitinomics Provides Insights into
616   Translation Regulation under Stress. *Journal of proteome research* **18**, 309–318 (2019).

617   42.   GM, S., D, F. & C, V. K63 polyubiquitination is a new modulator of the oxidative stress
618   response. *Nature structural & molecular biology* **22**, 116–123 (2015).

619   43.   L, W. *et al.* Arabidopsis UBC13 differentially regulates two programmed cell death
620   pathways in responses to pathogen and low-temperature stress. *The New phytologist*
621   **221**, 919–934 (2019).

622   44.   Lentucci, C. *et al.* Inhibition of Ubc13-mediated Ubiquitination by GPS2 Regulates
623   Multiple Stages of B Cell Development. *Journal of Biological Chemistry* **292**, (2017).

624   45.   Cardamone, M. *et al.* A Protective Strategy against Hyperinflammatory Responses
625   Requiring the Nontranscriptional Actions of GPS2. *Molecular Cell* **46**, (2012).

626   46.   Cederquist, C. T. *et al.* Systemic insulin sensitivity is regulated by GPS2 inhibition of AKT
627   ubiquitination and activation in adipose tissue. *Molecular Metabolism* **6**, 125–137 (2017).

47. Chan, S. *et al.* Loss of G-Protein Pathway Suppressor 2 Promotes Tumor Growth
Through Activation of AKT Signaling. *Frontiers in Cell and Developmental Biology* **8**,
(2021).

48. Cardamone, M. *et al.* GPS2/KDM4A pioneering activity regulates promoter-specific
recruitment of PPARγ. *Cell Reports* **8**, (2014).

49. Sims, J. J. *et al.* Polyubiquitin-sensor proteins reveal localization and linkage-type
dependence of cellular ubiquitin signaling. *Nature methods* **9**, 303 (2012).

50. Wetzler, M. & Segal, D. Omacetaxine as an Anticancer Therapeutic: What is Old is New
Again. *Current Pharmaceutical Design* **17**, 59–64 (2011).

51. Z, W. *et al.* Ubiquitination of ABCE1 by NOT4 in Response to Mitochondrial Damage
Links Co-translational Quality Control to PINK1-Directed Mitophagy. *Cell metabolism* **28**,
130-144.e7 (2018).

52. L, G. *et al.* A-kinase-anchoring protein 1 (dAKAP1)-based signaling complexes
coordinate local protein synthesis at the mitochondrial surface. *The Journal of biological*
chemistry **295**, 10749–10765 (2020).

53. D, P.-M. *et al.* CLUH granules coordinate translation of mitochondrial proteins with
mTORC1 signaling and mitophagy. *The EMBO journal* **39**, (2020).

54. Hildebrandt, A. *et al.* The RNA-binding ubiquitin ligase MKRN1 functions in ribosome-
associated quality control of poly(A) translation. *Genome Biology 2019 20:1* **20**, 1–20
(2019).

55. Sonenberg, N. & Hinnebusch, A. G. Regulation of Translation Initiation in Eukaryotes:
Mechanisms and Biological Targets. *Cell* **136**, 731 (2009).

56. A, K., YV, S., R, S., MN, M. & N, S. Mammalian poly(A)-binding protein is a eukaryotic
translation initiation factor, which acts via multiple mechanisms. *Genes & development*
19, 104–113 (2005).

57. Yoshida, M. *et al.* Poly(A) binding protein (PABP) homeostasis is mediated by the stability
of its inhibitor, Paip2. *The EMBO Journal* **25**, 1934 (2006).

58. Schäffler, K. *et al.* A stimulatory role for the La-related protein 4B in translation. *Rna* **16**,
1488–1499 (2010).

59. Lesnik, C., Golani-Armon, A. & Arava, Y. Localized translation near the mitochondrial
outer membrane: An update. *RNA Biology* **12**, 801–809 (2015).

60. Stavraka, C. & Blagden, S. The La-related proteins, a family with connections to cancer.
Biomolecules **5**, 2701–2722 (2015).

61. Eliyahu, E. *et al.* Tom20 Mediates Localization of mRNAs to Mitochondria in a
Translation-Dependent Manner. *Molecular and Cellular Biology* **30**, 284–294 (2010).
62. Schatton, D. *et al.* CLUH regulates mitochondrial metabolism by controlling translation
and decay of target mRNAs. *The Journal of Cell Biology* **216**, 675–693 (2017).
63. E, B., R, Z. & HM, M. MAPL is a new mitochondrial SUMO E3 ligase that regulates
mitochondrial fission. *EMBO reports* **10**, 748–754 (2009).
64. J, P., KD, R., J, Y. & XJ, L. Mitochondrial E3 ubiquitin ligase 1: A key enzyme in
regulation of mitochondrial dynamics and functions. *Mitochondrion* **28**, 49–53 (2016).
65. M, E.-H. & M, J. Mitofusins: Disease Gatekeepers and Hubs in Mitochondrial Quality
Control by E3 Ligases. *Frontiers in physiology* **10**, (2019).
66. R, P., XT, C., MY, L., N, H. & ZH, S. Mul1 restrains Parkin-mediated mitophagy in mature
neurons by maintaining ER-mitochondrial contacts. *Nature communications* **10**, (2019).
67. R, P., XT, C., MY, L., N, H. & ZH, S. Defending stressed mitochondria: uncovering the
role of MUL1 in suppressing neuronal mitophagy. *Autophagy* **16**, 176–178 (2020).
68. Neutzner, A., Benard, G., Youle, R. J. & Karbowski, M. Role of the ubiquitin conjugation
system in the maintenance of mitochondrial homeostasis. *Annals of the New York*
Academy of Sciences **1147**, 242–253 (2008).
69. Peng, J., Ren, K. di, Yang, J. & Luo, X. J. Mitochondrial E3 ubiquitin ligase 1: A key
enzyme in regulation of mitochondrial dynamics and functions. *Mitochondrion* **28**, 49–53
(2016).
70. W, L. *et al.* Genome-wide and functional annotation of human E3 ubiquitin ligases
identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and
signaling. *PloS one* **3**, (2008).
71. Y, Z. *et al.* Structural impact of K63 ubiquitin on yeast translocating ribosomes under
oxidative stress. *Proceedings of the National Academy of Sciences of the United States*
of America **117**, 22157–22166 (2020).
72. Back, S., Gorman, A. W., Vogel, C. & Silva, G. M. Site-Specific K63 Ubiquitinomics
Provides Insights into Translation Regulation under Stress. *Journal of Proteome*
Research **18**, 309–318 (2019).
73. F, B. *et al.* Comprehensive analysis of the ubiquitinome during oncogene-induced
senescence in human fibroblasts. *Cell cycle (Georgetown, Tex.)* **14**, 1540–1547 (2015).
74. Jensen, O. N., Wilm, M., Shevchenko, A. & Mann, M. Sample Preparation Methods for
Mass Spectrometric Peptide Mapping Directly from 2-DE Gels. *Methods in molecular*
biology (Clifton, N.J.) **112**, 513–530 (1999).

75.   Ong, S. E. *et al.* Stable isotope labeling by amino acids in cell culture, SILAC, as a simple

696   and accurate approach to expression proteomics. *Molecular & cellular proteomics : MCP*

697   **1**, 376–386 (2002).

 FIGURE LEGENDS

Figure 1 - Mitochondrial proteome of GPS2 WT and KO MEFs

A, Heatmap showing 137 significantly changed mitochondrial proteins induced by GPS2-

deficiency from GPS2 WT and KO MEFs. Enriched biological process GO terms of significantly

downregulated (blue, upper panels) or upregulated (red, down panels) in response to GPS2

deficiency.

B, Western blot analysis of SOD2, PDRX2, and FASN normalized to GAPDH in mitochondrial

extracts from WT versus GPS2 KO MEFs.

C&D, Distribution of 137 significantly changed mitochondrial proteins based on LC-MS/MS

analysis and RNA-seq (C) or previously generated GRO-seq in 3T3-L1 cells[9]. Red, upregulated

proteins identified through RNA-seq and proteomics; Blue, upregulated proteins identified through

proteomics, but downregulated in RNA-seq; Black, downregulated proteins identified through

proteomics.

Figure 2 - K63 ubiquitome profiling of GPS2 WT and KO MEFs by LC-MS/MS

A, Increased K63 ubiquitination in mitochondria extract in GPS2 KO compared to WT by western

blot.

B, SILAC-based K63 proteomic profiling of GPS2 WT and KO MEFs.

C, Gene ontology analysis of 46 putative K63 ubiquitinated proteins whose ubiquitination is

mediated by GPS2.

D, Detection of K63 ubiquitination of RPS11 and RACK1 purified by specific K63-ubiquitin binding

domain Vx3K0 by IP/WB using both whole-cell extracts and fractionated mitochondrial extracts in

GPS2 WT and KO MEFs.

E, Puromycin labeling of *de novo* protein synthesis on different fractionated extracts pretreated

w/o homoharringtonine (HHT). ME, mitochondrial extract; CE, cytosol extract; NE, nuclear extract;

WCL, whole cell extract. Cells were treated with HHT for 10 min prior to treatment with 0.9mM

puromycin for additional 5 min. Anti-GAPDH/B-Tub/HDAC2 blot was used as loading control for

different fractions.

Figure 3 - PABPC1 ubiquitination is mediated by Mul1 on mitochondria.

A, Detection of K63 ubiquitination of PABPC1 purified by specific K63-ubiquitin binding domain

Vx3K0 by IP/WB using both whole cell extracts and fractionated mitochondrial extracts in GPS2

WT and KO MEFs.

B, Detection of K63 ubiquitination by IP/WB of PABPC1 in mitochondria extracts in GPS2 WT,

KO and KO treatment with UBC13 inhibitor MEFs.

C, FCCP-induced ubiquitination of PABPC1 is mediated by mitochondria specific E3 ligase MUL1.

D, PABPC1 is polyubiquitinated by the E3 ubiquitin ligase MUL1 by *in vitro* ubiquitination assay.

E, Polyubiquitination on PABPC1 mediated by E3 ubiquitina ligase MUL1 is significantly inhibited

by GPS2 in *in vitro* ubiquitination assay.

F, WB analysis of binding of PABPC1 with EIF4G, PAIP1 and PAIP2 on mitochondrial extracts

from GPS2 WT and KO MEFs.

G, WB analysis of binding of PABPC1 with PAIP1 and PAIP2 on mitochondrial extracts from

GPS2 WT, KO and KO knockdown MUL1 (siMul1) MEFs.

H, Puromycin labeling of *de novo* protein synthesis on mitochondrial extracts from GPS2 WT, KO

and KO knockdown MUL1 (siMul1) MEFs. Anti-GAPDH blot was used as loading control.

Figure 4 - K63 ubiquitination-mediated regulation of mitochondrial-associated translation

in stress response

A, WB of fractionated extracts showing mitochondria-to-nucleus translocation of GPS2 in MEFs

cells upon FCCP treatment.

B, Detection of K63 ubiquitination by IP/WB of PABPC1 in mitochondria extracts in MEFs cells

upon FCCP treatment.

C, Detection of K63 ubiquitination of PABPC1 purified by specific K63-ubiquitin binding domain

Vx3K0 by IP/WB in mitochondria extracts in MEFs cells upon FCCP treatment.

D, WB analysis of binding of PABPC1 with PAIP1 and PAIP2 in mitochondria extracts in MEFs

cells upon FCCP treatment.

E, Heatmap showing significantly changed mitochondrial proteins in GPS2 WT, KO MEFS and

WT cells treated with FCCP for 3h and 12h .

F, Western blot analysis of SOD2 normalized to GAPDH in mitochondrial extracts in MEFs cells

upon FCCP treatment.

Supplemental Figure 1, Related to Figure 1

A, Western blot analysis of GPS2 expression in GPS2 WT and KO MEFs cells. Anti-a-Tub blot

was used as loading control.

B, Mitochondrial DNA content in WT and GPS2 KO MEFs cells. **indicate p-value<0.01.

C, Gene ontology analysis of 891 differentially expressed proteins induced by GPS2-deficiency

from GPS2 WT and KO MEFs.

Supplemental Figure 2, Related to Figure 2

A, Comparison of the binding affinity of Vx3K0 and Rx3 to different type and length ubiquitin

chains.

B, WB analysis of K63 ubiquitinated proteins captured by Vx3K0 from whole cell extracts in GPS2

WT and KO MEFs.

C, Scatter plotting analysis of SILAC data obtained from two independent SILAC-K63 ubiquitome

experiments. The KO/WT SILAC ratio of two labeled samples were converted to log2 scale for

analysis. The proteins identified by SILAC-K63 ubiquitome and their SILAC ratios are listed in

supplemental Table 3.

D, TMT labeling-based K63 proteomic profiling of GPS2 WT and KO MEFs. Each sample

(WT/KO) has 3 replicates for LC-MS/MS analysis.

E, Gene ontology analysis of 22 putative K63 ubiquitinated proteins whose ubiquitination are

mediated by GPS2 identified in MB231.

Supplemental Figure 3, Related to Figure 2

A, Venn diagram comparing identified putative K63 ubiquitinated proteins whose ubiquitination

are mediated by GPS2 from MEFs SILAC, MEFs TmT and MDA-MB231 SILAC datasets.

B, Detection of K63 ubiquitination of eif3M purified by specific K63-ubiquitin binding domain

Vx3K0 by IP/WB using fractionated mitochondrial extracts in GPS2 WT, KO and KO knockdown

Mulan (siMul1) MEFs.

Figure 1

Gao et al., 2021

Figure 2
Gao et al., 2021

Figure 3
Gao et al., 2021

Figure 4
Gao et al., 2021